Alex Rothman
@alex_rothman
fascinated
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study @atscommunity #PAH 🔓Open Access 🔗atsjournals.org/doi/full/10.11…
Love this sub stack on our Imatinib trial. The author completely ‘gets’ the big implications of our neat, nimble design. @alex_rothman @MRC_BSU @SofiaSVillar1 drugdevelop.substack.com/p/small-trials…
And the BCS Young Investigators award winner is Dan Taylor ! @drmorriscardio @ShefUni_ClinMed @insigneo

Congratulations to Prof Alexander Rothman who has received the Michael Davies Early Career Award at #BCS2025. We’re so proud to have been part of your research journey as you continue develop more accessible and empowering ways to treat people with Pulmonary Hypertension.
Packed house for the BCS Young Investigators session - fantastic presentations !

In the latest issue! Therapeutic potential of allosteric HECT E3 ligase inhibition dlvr.it/TKqmbX
The pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2 – watch the #HFASnacks where Julio Nunez Villota and @dana_dawson16 along with host @slumberbell discuss it. Only at…
Can Pulmonary Artery Denervation reshape the future of group 2 PH management? @YulNunezVill presents promising early data on #PADN using the Gradient Denervation System in HF patients with Group 2 PH: 📍 #PADN led to ⬆️ in pulmonary hemodynamics & ⬇️ #RV afterload in combined…
Great to be at my first ARCP as dTPD for cardiology in South Yorkshire yesterday. Such world class cardiology talent being nurtured in the steel city & it’s surrounds. @VarianFrances @DrMarkMills @RyanCrapper @drfmejaz @RebeccaGosling3 & others.